TPX 100

Drug Profile

TPX 100

Alternative Names: TPX-100

Latest Information Update: 08 Sep 2016

Price : $50

At a glance

  • Originator OrthoTrophix
  • Class Antirheumatics; Glycoproteins
  • Mechanism of Action Collagen modulators; Extracellular matrix protein modulators; Integrin stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Osteoarthritis

Most Recent Events

  • 22 Jul 2016 OrthoTrophix plans a phase II trial for Osteoarthritis in USA (NCT02837900)
  • 18 Apr 2016 Phase-II development is ongoing in USA (Intra-articular)
  • 21 May 2015 OrthoTrophix completes enrolment in its phase II trial for Osteoarthritis in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top